Separately, Zacks Investment Research upgraded Kamada from a “hold” rating to a “buy” rating and set a $6.25 price objective for the company in a research report on Wednesday, April 13th.
Shares of KMDA stock opened at $5.37 on Wednesday. The firm’s 50-day moving average price is $5.67. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.16 and a current ratio of 2.41. The firm has a market cap of $239.07 million, a PE ratio of -107.38 and a beta of 1.05. Kamada has a twelve month low of $5.11 and a twelve month high of $6.96.
Several institutional investors have recently made changes to their positions in KMDA. Phoenix Holdings Ltd. raised its position in shares of Kamada by 39.3% during the fourth quarter. Phoenix Holdings Ltd. now owns 1,284,137 shares of the biotechnology company’s stock worth $8,450,000 after purchasing an additional 362,474 shares during the period. Altshuler Shaham Ltd boosted its stake in shares of Kamada by 2.5% during the 3rd quarter. Altshuler Shaham Ltd now owns 927,474 shares of the biotechnology company’s stock worth $4,941,000 after acquiring an additional 22,222 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of Kamada by 1.5% during the 4th quarter. Wells Fargo & Company MN now owns 454,137 shares of the biotechnology company’s stock worth $2,988,000 after acquiring an additional 6,829 shares in the last quarter. BlackRock Inc. boosted its stake in Kamada by 1,091.3% during the 4th quarter. BlackRock Inc. now owns 227,660 shares of the biotechnology company’s stock valued at $1,498,000 after purchasing an additional 208,549 shares during the period. Finally, Morgan Stanley boosted its stake in Kamada by 10.7% during the 2nd quarter. Morgan Stanley now owns 206,619 shares of the biotechnology company’s stock valued at $1,203,000 after purchasing an additional 19,953 shares during the period. Institutional investors and hedge funds own 20.41% of the company’s stock.
About Kamada (Get Rating)
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to AATD, KAMRAB/KEDRAB a plasma-derived hyper- immunoglobulin for prophylactic treatment against rabies infection.
- Get a free copy of the StockNews.com research report on Kamada (KMDA)
- The Sherwin-Williams Company Bottoms Above Institutional Support
- Simpson Manufacturing Co. Hits The Nail On The Head, Again
- What To Make Of Activision Blizzard (NASDAQ: ATVI)
- Whirlpool Is A Steal At These Prices
- Kimberly-Clark Pops On Successful Price Pass-Through
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.